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BACKGROUND. At 5-year follow-up, patients with Paget disease of the breast who
were treated with breast-conserving surgery (BCS) and radiotherapy (RT) had
excellent results. The current report provides 10- and 15-year rates of tumor
control in the breast, as well as disease-free and overall survival rates following BCS
and RT in a cohort of patients with Paget disease presenting without a palpable
mass or mammographic density.
METHODS. Through a collaborative review of patients treated with BCS and RT
from seven institutions, 38 cases of Paget disease of the breast presenting
without a palpable mass or mammographic density were identified. All patients
had pathologic confirmation of typical Paget cells at time of diagnosis. Thirty-
six of 38 patients had a minimum follow-up greater than 12 months and
constitute the study cohort. Ninety-four percent of patients underwent com-
plete or partial excision of the nipple-areola complex and all patients received
a median external beam irradiation dose of 50 Gy (range, 45–54 Gy) to the
whole breast. Ninety-seven percent of patients also received a boost to
the remaining nipple or tumor bed, a median total dose of 61.5 Gy (range,
50.4 –70 Gy).
RESULTS. With median follow-up of 113 months (range, 18 –257 months), 4 of 36
patients (11%) developed a first recurrence of disease in the treated breast only.
Two of the four recurrences in the breast were ductal carcinoma in situ (DCIS)
only and two were invasive with DCIS. Two additional patients had a recurrence
in the breast as a component of first failure. Actuarial local control rates for the
breast as the only site of first recurrence were 91% at 5 years (95% confidence
interval [CI], 80 –100%) and 87% (95% CI, 75–99%) at both 10 and 15 years.
Actuarial local control rates for breast recurrence, as a component of first
failure, were 91% (95% CI, 80 –100%), 83% (95% CI, 69 –97%), and 76% (95% CI,
58 –94%) at 5, 10, and 15 years, respectively. No clinical factors were identified
as significant predictors for breast recurrence. Five-, 10- and 15-year actuarial
rates for survival without disease of 97% (95% CI, 90 –100%) and 5-, 10-, and
15-year actuarial rates of overall survival of 93% (95% CI, 84 –100%) at 5 years
and 90% (95% CI, 78 –100%) at 10 and 15 years were reported.
CONCLUSIONS. These data confirm excellent rates of local control, disease-free
survial, and overall survival at 10 and 15 years following BCS and RT for Paget
disease of the breast. This study continues to support the recommendation of
local excision and definitive breast irradiation as an alternative to mastectomy
in the treatment of patients with Paget disease presenting without a palpable
mass or mammographic density. Cancer 2003;97:2142–9.
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Paget disease of the breast represents 1–3% of allbreast malignancies1–5 and is characterized patho-
logically by the presence of round intraepidermal cells
of the nipple. Although the majority of cases of Paget
disease will have an underlying breast malignancy,1– 4
previous studies of patients treated with mastectomy
have identified two distinct clinical presentations with
associated histologic findings.1,5 Approximately 90%
of patients presenting with a palpable or mammo-
graphic mass will have an underlying invasive carci-
noma. Conversely, 66 – 86% of patients without a clin-
ical mass on physical examination or mammogram
will have ductal carcinoma in situ (DCIS) alone.1,5
Prognosis is determined primarily by the presence or
absence of an invasive component,1,2,5 and recom-
mendations for systemic therapy have been suggested
accordingly.
The role of breast-conserving surgery (BCS) with
radiotherapy (RT) for selected patients with Paget dis-
ease, however, has not been defined fully. Multiple
randomized trials have found BCS and RT to be an
acceptable alternative and often preferable option to
mastectomy for patients with early-stage invasive
breast carcinoma. Randomized trials also have con-
firmed the highly successful results of BCS and RT in
the treatment of patients with DCIS.6 – 8 However, due
to the rarity of Paget disease of the breast, a prospec-
tive, randomized trial comparing BCS and RT to mas-
tectomy is unlikely to be feasible. Therefore, several
retrospective studies have reviewed limited experi-
ence with RT alone or conservative surgery with or
without the addition of RT in the treatment of Paget
disease, but the analyses are limited by small patient
numbers with limited follow-up and/or variation in
clinical presentation.2,9 –13 The current report presents
an analysis of a collaborative series from seven insti-
tutions comprising patients with Paget disease of the
breast presenting with nipple changes in the absence
of a palpable mass or mammographic density who
were treated with BCS and RT. Rates of local control
and disease-free and overall survival at 5 years were
reported previously.14 We report the results with ex-
tended follow-up at 10 and 15 years.
MATERIALS AND METHODS
All patients diagnosed with Paget disease of the breast
without a palpable mass or mammographic density
and treated with BCS and RT between 1980 and 2000
at 7 collaborating institutions were identified. Patients
were treated with breast conservation based on pa-
tient preference. No patients were referred for RT due
to contraindications to surgery. Previously reported
cases were updated by the originating institutions
with respect to date of last follow-up, survival status,
patterns of failure and complications, as appropriate.
All new cases identified since the previous analysis
and treated with BCS and RT were added to the data-
set and included in the current analysis. Thirty-eight
cases of Paget disease of the breast were identified
from the following institutions: 10 from the University
of Michigan, 9 from Yale University, 5 each from the
University of Pennsylvania and William Beaumont
Hospital, 4 from Memorial Sloan-Kettering Cancer
Center, 3 from Tufts University, and 2 cases from Beth
Israel Deaconess Medical Center. Due to follow-up
limited to less than 12 months, two patients were
excluded from the current analysis.
Each patient had a nipple biopsy demonstrating
typical Paget cells at the time of diagnosis. A central
pathology review was not performed. Thirty-three
women were diagnosed with American Joint Commit-
tee on Cancer TisN0M0, Stage 0 Paget disease of the
breast.15 Two patients were diagnosed with T1N0M0,
Stage I Paget disease, one with microinvasion and one
with invasive ductal carcinoma measuring 0.5 cm. One
patient had T2N0M0, Stage IIA disease with a mam-
mographically occult invasive ductal and lobular car-
cinoma measuring 2.7 cm located directly beneath the
nipple-areolar complex.
Surgery consisted of either a complete or partial
excision of the nipple-areolar complex. Twenty-five
patients (69%) underwent a complete excision, 9 pa-
tients (25%) a partial excision, and 2 (6%) underwent a
biopsy alone. Final margins were negative in 20 cases
(56%), positive in 2 (6%), and unknown in 14 (39%).
Fourteen patients (39%) had an axillary lymph node
dissection, with a median of 13 lymph nodes resected
(range, 8 –24 lymph nodes), and one patient had a
sentinel lymph node biopsy (four lymph nodes were
removed). All patients received RT using tangential
fields to the whole breast. The median dose delivered
was 50 Gy (range, 45–54 Gy) with median fraction size
of 2 Gy (range, 1.8 –2 Gy). An area of increased dose
(underwedging) in the nipple-areolar region was iden-
tified in seven RT plans, each with a maximum isodose
of 106 –110%. A boost was delivered to the remaining
nipple or tumor bed in 97% of cases to a median dose
of 14 Gy (range, 9 –20 Gy). The median total dose to
the tumor bed was 61.5 Gy (range, 50.4 –70 Gy). Of the
35 patients receiving a boost, 29 patients (81%) were
treated with electrons, 1 patient (3%) received both
electrons and photons, and 3 patients (9%) were
treated using photons only. Two women (6%) received
a boost using a low dose rate interstitial implant. Bolus
was used in the photon and/or electron portion of
treatment in 10 cases (27%), bolus was not used in 24
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(67%) cases, and it is unknown whether bolus was
used in 2 cases. The location of the placement of bolus
was highly variable between institutions. Bolus was
applied to the scar or remaining nipple-areolar com-
plex during whole breast RT in six patients, to the
breast and scar boost in two patients, and to the scar
boost only in two patients. In addition to breast irra-
diation, one patient received supraclavicular RT to a
dose of 46 Gy and a second patient was treated com-
prehensively to the supraclavicular, axillary, and inter-
nal mammary lymph nodes to a total dose of 50 Gy.
Two patients (6%) received systemic treatment with
tamoxifen.
Patient records were reviewed for the following
characteristics: age, menopausal status, presenting
symptoms, duration of symptoms, mammographic
findings, extent of surgical excision, final margin sta-
tus, pathologic findings, and dissection of axillary
lymph nodes with pathologic results. Actuarial curves
for local control, disease-free survival, and overall sur-
vival were generated using the Kaplan–Meier method
measured from the completion of RT.16 A local recur-
rence as only first recurrence was defined as a recur-
rence in the breast without preceding or simultaneous
regional or distant disease. Local recurrence as a com-
ponent of first recurrence included all patients who
developed a breast recurrence either as an isolated
recurrence or concurrent with regional and/or distant
recurrence. Time to local recurrence was defined as
the time between completion of RT and the date of
recurrence. Patients were scored as having no evi-
dence of disease (NED) at last observation if they had
been continuously free of disease from the completion
of RT to the last follow-up visit or had developed local
and/or regional recurrence that was successfully sal-
vaged at the last observation period. For the calcula-
tion of cause-specific survival, only deaths secondary
to breast carcinoma were scored as events.
Paget cases identified since the previous analysis
were added to the existing cases, and univariate anal-
yses were performed using the Fisher exact test to
evaluate the association between clinical characteris-
tics and local control.
RESULTS
Clinical and Pathologic Findings
Thirty-six patients with a follow-up greater than 12
months were identified. Median age at diagnosis was
51 years (range, 33–79 years). Patient characteristics
and mammographic and pathologic findings are sum-
marized in Table 1. All patients were symptomatic at
presentation with a median duration of symptoms of 9
months (range, 1–36 months).
Pathologic review at the time of diagnosis re-
vealed typical Paget cells of the nipple in all 36 cases.
Thirty cases (83%) had an underlying malignancy. Of
the remaining six cases, two patients had no underly-
ing breast parenchyma resected and four had no DCIS
or invasion present. Among the 15 patients who un-
derwent axillary lymph node surgery, all lymph nodes
were pathologically negative for metastatic disease.
Of six patients with mammographic calcifications
(17%), 4 had a postoperative mammogram. Three
showed no residual calcifications and one showed
residual subareolar microcalcifications. No further
surgery was performed on this patient before RT.
Local Control, Cosmesis, and Complications
Median follow-up for surviving patients was 113
months (range, 17–257 months). Table 2 shows the 5-,
TABLE 1
Clinical, Mammographic, and Pathologic Characteristics







Eczematous changes 21 (58)




Negative for malignancy 27 (77)
Abnormality detecteda 8 (23)
Nipple thickening 3
Subareolar calcifications only 3
Breast calcifications elsewhere 3
Extent of nipple-areolar excision
Complete nipple-areolar complex 25 (69)
Partial nipple-areolar complex 9 (25)





Underlying malignancy 30 (83)
DCIS only 27 (75)
DCIS and invasive carcinoma 2 (6)





DCIS: ductal carcinoma in situ.
a One patient had both nipple thickening and subareolar calcifications.
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10-, and 15-year actuarial local control rates for the
breast as the only site of first recurrence and as a
component of first recurrence. Actuarial curves for
local recurrence are presented in Figure 1.
Four of 36 patients (11%) developed local disease
recurrence 21– 69 months after completion of RT. Sur-
gical margins at primary surgery were negative in two
patients and unknown in the other two patients. All
patients had undergone complete resection of the nip-
ple-areolar complex at primary surgery, although a
postoperative mammogram showed residual subare-
olar microcalcifications in one patient. All were suc-
cessfully salvaged by mastectomy. Pathologic findings
indicated DCIS only in two patients and DCIS with
invasive disease in the remaining two patients.
Two additional patients (6%) developed an in-
breast recurrence simultaneously with either regional
or distant recurrence. Pathology revealed invasive and
intraductal disease in both cases. Time to local recur-
rence for these patients was 69 months and 122
months, respectively. Both had a partial nipple-areolar
complex excision at primary surgery with final margin
status unknown. One woman experienced a simulta-
neous breast and axillary lymph node recurrence and
was treated by mastectomy and axillary lymph node
dissection followed by chemotherapy and tamoxifen.
She has remained free of disease at last follow-up 11.9
years after disease recurrence. The second patient had
a simultaneous recurrence in the breast and contralat-
eral axilla 10.5 years following initial diagnosis. A di-
agnostic biopsy of the treated breast was performed at
that time. It confirmed recurrent disease, but no at-
tempt was made to perform a mastectomy. The pa-
tient died with disease 5.5 years following recurrence.
At the time of last follow-up, local disease control
was obtained for 35 of 36 patients (97%), either by
primary treatment (30 of 36; 83%) or salvage surgery (5
of 5 patients). Actuarial curves of local control with
and without surgical salvage are shown in Figure 2.
None of the patients with evidence of invasive carci-
noma at the time of primary surgery experienced dis-
ease recurrence.
Univariate analysis for local failure as a compo-
nent of first failure was performed for a number of
clinical, pathologic, and treatment factors (Table 3).
No factors significantly predicted the risk of local dis-
ease recurrence.
Cosmesis was assessed using the criteria sug-
gested by Harris et al.17 Ten of 31 patients (32%) were
considered by the treating radiation oncologist to have
an excellent result, including 4 patients who under-
went nipple reconstruction after complete nipple-are-
olar resection. Eighteen patients (58%) were consid-
ered to have a good result and 3 patients (10%) a fair
result.
TABLE 2
Actuarial Local Control Rates for the Breast as the Only Site of First
Recurrence and as a Component of First Recurrence
Year Control rate (%) 95% Confidence interval








FIGURE 1. Actuarial rates of local recurrence in the breast as the only site
of first recurrence and as a component of first failure.
FIGURE 2. Actuarial rates of local control with and without surgical salvage.
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Complications were assessed in 32 of 36 cases,
with 91% (29 patients) having no long-term complica-
tions. In addition, one patient developed protracted
chest wall pain, one developed chronic breast infec-
tion, and one possible radiation dermatitis requiring
steroids.
Cause-Specific and Overall Survival Rates
At last follow-up, 32 of 36 patients (89%) had NED.
Two patients (6%) died with disease, and 2 died free of
disease. The two patients who died with disease both
had a previous breast recurrence. One woman had a
simultaneous recurrence in the contralateral axilla
and the second patient had a breast cancer recurrence
69 months after completion of RT and underwent a
successful salvage mastectomy. However, she devel-
oped bone metastases 22 months after breast recur-
rence and died 5 months thereafter.
Actuarial curves for cause-specific survival and
overall survival at 5, 10, and 15 years are provided in
Figure 3. The actuarial rate for breast carcinoma-spe-
cific survival was 97% at 5, 10, and 15 years (95%
confidence interval [CI], 90 –100%). Actuarial rates for
overall survival were 93% (95% CI, 84 –100%) at 5 years
and 90% (95% CI, 78 –100%) at 10 and 15 years. One
patient with disease died at 15.6 years, giving an over-
all survival beyond 15 years of 75% (95% CI, 46 –100%).
DISCUSSION
The current study represents an update of the collab-
orative series reported by Pierce et al.14 of patients
with Paget disease of the breast presenting without a
palpable mass or mammographic density treated with
BCS and RT. In the Pierce et al. report, the 5- and
8-year local control rates with the breast as the only
site of first recurrence were 91% and 84%, respectively,
the 5- and 8-year disease-free survival rate was 95%,
and the 8-year cause-specific overall survival rate was
100%. These results suggested that for selected pa-
tients with Paget disease of the breast, BCS and RT was
a viable alternative to mastectomy. In the current ar-
ticle, the local control rate of 87% at 10 and 15 years,
the cause-specific survival rate of 97% at 10 and 15
years, and the overall survival rate of 90% at 10 and 15
years add further support to the original conclusions.
Small series have shown increased rates of recur-
rence in the breast following BCS only, with rates of
recurrence of 20 – 60% at 12–19 months following sur-
gery.18 –20 A recent report by Polgar et al.21 of 33 pa-
tients identified in the database of the National Insti-
tute of Oncology, Budapest, Hungary, as being treated
with cone excision alone represents the largest series
ever reported of BCS only. The median age of the
patients in their study was 65 years compared with a
median age of 51 years in the current study. Ninety-
TABLE 3







Negative 27 19  0.99
Calcifications 8 13
Not done 1 0
Extent of nipple-areolar excision
Complete nipple-areolar complex 25 16 0.65
Partial nipple-areolar complex 9 22
Not done 2 0
Final margin status




Paget disease only 6 0 0.56
Paget disease with DCIS with/without
invasion 30 20
Breast dose (Gy)
 50 13 15  0.99
 50 23 17
Dose to tumor bed with boost (Gy)
 60 4 0  0.99
 60 32 19
Use of bolus




a Fisher exact test computed for known clinical factor categories only.
FIGURE 3. Actuarial rates of cause-specific survival and overall survival.
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one percent of cases in the Polgar et al. study were not
associated with a palpable mass, compared with 100%
in the current study. In addition, DCIS was identified
in 91% of cases versus 75% in the current study. There
were no cases of invasive cancer identified in the
series from Hungary. With a median of 6.0 years of
follow-up (range, 2–14 years), the crude local recur-
rence rate was 33% (11 of 33), with a 5-year actuarial
recurrence rate of 28%. Disease recurrence was inva-
sive in 10 of the 11 patients. Six of these patients
developed distant metastases and all have subse-
quently died of breast carcinoma. These data demon-
strate that Paget disease of the breast should not be
treated with cone excision only. As stated by the au-
thors, “RT is mandatory after breast-conserving sur-
gery to maintain adequate local control” (p. 1905).21
Although direct comparisons cannot be made across
series, similar clinicopathologic characteristics be-
tween the patients in the surgery-only series and the
current study suggest a significant reduction in ipsi-
lateral breast recurrence and improvement in disease-
specific survival in patients treated with breast irradi-
ation.
Other studies have reported the outcome of Paget
disease treated with limited surgery and definitive
RT.10,12,22 In a recent report, the European Organiza-
tion for Research and Treatment of Cancer (EORTC)22
presented their results of a cohort of 61 patients with
Paget’s disease treated with BCS and RT. With a me-
dian follow-up of 6.4 years, the 5-year local recurrence
rate was estimated to be 5.2% compared with the 9%
local recurrence rate in the current study. Again, dif-
ferences in patient selection and treatment between
the two studies preclude direct comparisons between
the results. However, some differences should be un-
derscored. The median age of patients in the current
study was 51 years compared with 58 years in the
EORTC study. The EORTC study included patients
with a palpable lesion but excluded patients with his-
tologic evidence of invasive carcinoma, which was
present in 8% of patients in the current study. All
patients in the EORTC study received a complete ex-
cision of the nipple-areolar complex and margins were
required to be histologically tumor free. This com-
pares to a complete nipple-areolar excision in 69% of
patients in the current study with only 56% of speci-
mens with margins known to be free of microscopic
disease. Repeat mammography was performed in all
EORTC patients 6 weeks postoperatively before RT
whereas only four of the six patients with suspicious
calcifications underwent repeat mammography be-
fore RT in the current study. Although susbsequent
analyses of the EORTC study are required to assess
sustained rates of local control, we concur with the
need to obtain negative margins of excision and a
postbiopsy mammogram negative for residual suspi-
cious microcalcifications before proceeding with
breast conservation. These recommendations are in
keeping with current practice guidelines in the treat-
ment of both invasive cancer and DCIS.
In almost all patients diagnosed with Paget dis-
ease of the breast, underlying carcinoma, either inva-
sive or intraductal, will be identified which will deter-
mine prognosis. In patients with Paget disease and no
palpable or mammographic mass, the majority will
have underlying DCIS. Therefore, axillary lymph
nodes are generally pathologically negative as shown
in the current report, and treatment should be di-
rected to the breast. For patients with Paget disease
presenting with nipple changes alone, the available
data support treatment consistent with an assumed
underlying DCIS. Conservative management of DCIS
using BCS and RT has been highly successful. Two
randomized trials have demonstrated significant re-
duction in the risk of local recurrence including inva-
sive recurrence in patients receiving whole breast RT
following lumpectomy.7,8 Rates of local control in
these series have approximated 90% at 5 years, similar
to the 91% rate in the current study.
Long-term follow-up data are particularly impor-
tant for patients with DCIS because DCIS generally
has a longer median time to recurrence than invasive
carcinoma. In addition, the median time to recurrence
following lumpectomy and RT for DCIS is longer than
that following lumpectomy alone.7,23 One report sug-
gested a median time to recurrence of 8 years or
more.24 Solin et al.25 reported that patients with mam-
mographically detected DCIS treated with BCS and RT
had a 15-year cause-specific survival rate of 98%, with
an overall survival rate of 92%. These rates are com-
parable to those found in the current study, in which
the 15-year cause-specific survival rate was 97% and
the overall survival rate was 90%. The 15-year rate of
local-only recurrence as first recurrence was 14%
compared with 13% in the current study and the me-
dian time to local recurrence was 5 years. This was
also a multi-institutional collaborative study with a
median follow-up of 9.4 years. With the selection cri-
teria used in the current study, the long-term results of
patients with Paget disease of the breast treated with
definitive irradiation are highly concordant with re-
sults achieved in patients with known DCIS.
Treatment of DCIS by mastectomy, previously the
treatment of choice, does not necessarily result in a
100% cure rate. A metaanalysis of mastectomy pa-
tients reported a breast carcinoma-specific mortality
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rate of 1.7% at 8.6 years of follow-up.26 Similarly, the
use of mastectomy for Paget disease has also re-
sulted in high rates of local control and surviv-
al.2,27,28 Some studies, however, report invasive re-
currences following surgery. Dixon et al.2 reported a
5% rate of locoregional invasive recurrence in 2 of
37 patients with Paget disease of the breast present-
ing without a palpable mass following mastectomy.
These patients were successfully salvaged however,
and remain disease free after 8 years of follow-up.
Although the use of mastectomy may result in im-
proved local control compared with breast-conserv-
ing therapy, there are obvious cosmetic and psycho-
logical consequences. Breast-conserving treatment
for Paget disease and DCIS must aim to minimize
local recurrence and achieve excellent rates of dis-
ease-free and overall survival as demonstrated in
the current study. The extent of resection and the
adequacy of margins are known factors predictive of
local control in the conservative management of
DCIS.29,30 Although the current study was unable to
demonstrate any statistically significant difference
in local control for the clinical factors studied, com-
plete excision of all underlying carcinoma should be
one of the aims of treatment. For this reason, the
authors continue to recommend that the treatment
of Paget disease should include excision of the en-
tire nipple-areolar complex, achievement of nega-
tive microscopic margins, and removal of all suspi-
cious microcalcifications seen on pre-treatment
mammograms before proceeding with definitive RT.
To the best of our knowledge, the current study
has the longest median follow-up of any reported se-
ries of patients treated with BCS and definitive RT for
Paget disease of the breast. Identification of factors
associated with local recurrence was not possible in
the current study due to the limitations of the small
sample of patients and variation in treatment due to
the collaborative nature of the study and the time
period over which the cases were collected. Other
limitations include incomplete information regarding
the final pathology margins in 39% of the patients in
this series and the absence of a post-operative mam-
mogram to rule out residual microcalcifications in all
patients presenting with suspicious microcalcifica-
tions. Despite these limitations, this study demon-
strates excellent rates of local control, cause-specific
survival, and overall survival at 10 and 15 years. The
authors confirm that BCS and RT is an appropriate
alternative to mastectomy in women with Paget dis-
ease of the breast presenting without evidence of a
palpable mass or mammographic density.
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